The prognostic landscape of tumor-infiltrating immune cell and immunomodulators in lung cancer
The prognostic landscape of tumor-infiltrating immune cell and immunomodulators in lung cancer
复制标题
DOI：
10.1016/j.biopha.2017.08.003
复制
发表时间：
2017-11-01
影响因子：
7.5
通讯作者：
Hou, Zhihua
中科院分区：
文献类型：
--
作者：
Liu, Xinyan;Wu, Shucai;Hou, Zhihua
肿瘤浸润免疫细胞与临床结果密切相关。然而，基于免疫化学的肿瘤浸润分析可能会产生误导，因为免疫亚群的代表性标志物可能在其他细胞类型中表达。在这项研究中，基于多基因方法（称为CIBERSORT）和在线数据库，癌症免疫组图谱（https：//tcia.at/），我们全面分析了肺腺癌（LUAD）和肺鳞状细胞癌（LUSC）中存在的肿瘤浸润免疫细胞。在LUAD（n = 492）和LUSC（n = 488）中评价了总共22种类型的适应性和先天性肿瘤浸润免疫细胞。因此，缺乏记忆B细胞或M0巨噬细胞数量增加的肿瘤与LUAD早期临床阶段的不良预后相关。在LUSC中，T滤泡辅助细胞与良好的结局相关，而中性粒细胞数量增加则预示着不良结局。此外，免疫检查点分子预后价值的Kaplan-Meier分析显示，ICOS的表达与LUAD患者的临床结局呈正相关。总的来说，我们的数据表明，肺癌中的肿瘤浸润免疫细胞可能是预后和免疫治疗反应的重要决定因素。(C)2017年由Elsevier Masson SAS出版。
Tumor-infiltrating immune cells are closely associated with clinical outcome. However, immunohistochemistry-based analysis of tumor infiltrates can be misleading as the representative marker of an immune subpopulation might be expressed in other cell types. In this study, based on a metagene approach (known as CIBERSORT) and an online databse, The Cancer Immunome Atlas (https://tcia.at/),we comprehensively analyzed the tumor-infiltrating immune cells present in lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC). A total of 22 types of both adaptive and innate tumor-infiltrating immune cells were evaluated in LUAD (n = 492) and LUSC (n = 488). As a result, tumors lacking memory B cells or with increased number of M0 macrophages were associated with the poor prognosis in LUAD at early clinical stage. In LUSC, T follicular helper cells were associated with favorable outcome, while increased number of neutrophils predicted a poor outcome. Moreover, Kaplan-Meier analysis of the prognostic value of immune checkpoint molecules revealed that expression of ICOS was positively correlated the clinical outcome of patients with LUAD. Collectively, our data suggest that tumor-infiltrating immune cells in lung cancer are likely to be important determinants of both prognosis and response to immunotherapies. (C) 2017 Published by Elsevier Masson SAS.